China myocardial infarction (MI) market is estimated to grow modestly at a CAGR of around 7.6% during the forecast period. Increasing heart attacks in the country is projected to increase the myocardial infarction market in China. According to the WHO, CVD causes one-third of the total fatalities each year in China. As per the Institute for Health Metrics and Evaluation, the incidence of CVD is increasing continuously in the country. The incidence reached 13.5 million in 2017 as compared to 12.5 million in 2014. The country is expected to have a significant market share in the myocardial infarction treatment market. As per International Trade Administration, in 2018, the global medical device market is around 42% of the size of the pharmaceuticals market, however, in China, it is around 14% only, which express a significant growth potential of the sector. The medical device market is one of the fastest-growing markets in China with double-digit growth for over a decade.

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

The companies which are contributing to the growth of China myocardial infarction market include AstraZeneca PLC, Bayer AG, Lifetech Scientific Corp., Abbott Laboratories Inc., GlaxoSmithKline PLC, Pfizer Inc., Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market. For instnace, in July 2018, Lifetech Scientific Corp. collaborated with Medtronic, an Ireland-based medical device manufacturer. This collaboration was aimed to combine the unique technologies of the two companies to provide highly advanced pacemakers to the heart patients in China.

Research Methodology

The market study of the China myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

1. China Myocardial Infarction Market Research and Analysis by Type
2. China Myocardial Infarction Market Research and Analysis by Device
3. China Myocardial Infarction Market Research and Analysis by Diagnosis
4. China Myocardial Infarction Market Research and Analysis by Treatment
5. China Myocardial Infarction Market Research and Analysis by End-Users

The Report Covers

• Comprehensive research methodology of the China myocardial infarction market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the China myocardial infarction market.
• Insights about market determinants which are stimulating the China myocardial infarction market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.